{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T06:34:53Z","timestamp":1769927693509,"version":"3.49.0"},"reference-count":12,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2021]]},"DOI":"10.3960\/jslrt.20045","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T22:15:18Z","timestamp":1610057718000},"page":"48-52","source":"Crossref","is-referenced-by-count":5,"title":["Transient atelectasis due to hilar lymph node swelling affected by                    lenalidomide-induced tumor flare reaction"],"prefix":"10.3960","volume":"61","author":[{"given":"Takahiro","family":"Suyama","sequence":"first","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terue","family":"Yui","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuo","family":"Horiuchi","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rie","family":"Irie","sequence":"additional","affiliation":[{"name":"Pathology, Nippon Koukan Hospital, Kawasaki,                            Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiyuki","family":"Osamura","sequence":"additional","affiliation":[{"name":"Pathology, Nippon Koukan Hospital, Kawasaki,                            Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Miyao","sequence":"additional","affiliation":[{"name":"Departments of Internal Medicine,Nippon Koukan Hospital, Kawasaki, Kanagawa, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Chiu                            H,                                Trisal                            P,                                Bjorklund                            C                    <i>et al.<\/i> Combination lenalidomide-rituximab immunotherapy                    activates anti-tumour immunity and induces tumour cell death by complementary                    mechanisms of action in follicular lymphoma. Br J Haematol. 2019; 185:                    240-253.","DOI":"10.1111\/bjh.15797"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Chanan-Khan                            AA,                                Chitta                            K,                                Ersing                            N                    <i>et al.<\/i> Biological effects and clinical significance of                    lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic                    leukaemia: in vivo evidence of immune activation and antitumour response. Br J                    Haematol. 2011; 155: 457-467.","DOI":"10.1111\/j.1365-2141.2011.08882.x"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Chanan-Khan                            A,                                Miller                            KC,                                Takeshita                            K                    <i>et al.<\/i> Results of a phase 1 clinical trial of thalidomide in                    combination with fludarabine as initial therapy for patients with                    treatment-requiring chronic lymphocytic leukemia (CLL). Blood. 2005; 106:                    3348-3352.","DOI":"10.1182\/blood-2005-02-0669"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Chanan-Khan                            A,                                Miller                            KC,                                Musial                            L                    <i>et al.<\/i> Clinical efficacy of lenalidomide in patients with                    relapsed or refractory chronic lymphocytic leukemia: results of a phase II                    study. J Clin Oncol. 2006; 24: 5343-5349.","DOI":"10.1200\/JCO.2005.05.0401"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Taleb                            BA. Tumour flare                    reaction in cancer treatments: a comprehensive literature review. Anticancer                    Drugs. 2019; 30: 953-958.","DOI":"10.1097\/CAD.0000000000000814"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Wolchok                            JD,                                Hoos                            A,                                O\u2019Day                            S                    <i>et al.<\/i> Guidelines for the evaluation of immune therapy activity                    in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15:                    7412-7420.","DOI":"10.1158\/1078-0432.CCR-09-1624"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Andritsos                            LA,                                Johnson                            AJ,                                Lozanski                            G                    <i>et al.<\/i> Higher doses of lenalidomide are associated with                    unacceptable toxicity including life-threatening tumor flare in patients with                    chronic lymphocytic leukemia. J Clin Oncol. 2008; 26:                    2519-2525.","DOI":"10.1200\/JCO.2007.13.9709"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Leonard                            JP,                                Trneny                            M,                                Izutsu                            K                    <i>et al.<\/i> AUGMENT: a phase III study of lenalidomide plus                    rituximab versus placebo plus rituximab in relapsed or refractory indolent                    lymphoma. J Clin Oncol. 2019; 37: 1188-1199.","DOI":"10.1200\/JCO.19.00010"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Wang                            M,                                Fowler                            N,                                Wagner-Bartak                            N                    <i>et al.<\/i> Oral lenalidomide with rituximab in relapsed or                    refractory diffuse large cell, follicular and transformed lymphoma: a phase II                    clinical trial. Leukemia. 2013; 27: 1902-1909.","DOI":"10.1038\/leu.2013.95"},{"key":"10","doi-asserted-by":"crossref","unstructured":"11 Chanan-Khan                            A,                                Miller                            KC,                                Lawrence                            D                    <i>et al.<\/i> Tumor flare reaction associated with lenalidomide                    treatment in patients with chronic lymphocytic leukemia predicts clinical                    response. Cancer. 2011; 117: 2127-2135.","DOI":"10.1002\/cncr.25748"},{"key":"11","doi-asserted-by":"crossref","unstructured":"12 Goy                            A,                                Sinha                            R,                                Williams                            ME                    <i>et al.<\/i> Single-agent lenalidomide in patients with mantle-cell                    lymphoma who relapsed or progressed after or were refractory to bortezomib:                    phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013; 31:                    3688-3695.","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"12","doi-asserted-by":"crossref","unstructured":"13 Chong                            EA,                                Ahmadi                            T,                                Aqui                            NA                    <i>et al.<\/i> Combination of lenalidomide and rituximab overcomes                    rituximab resistance in patients with indolent B-cell and mantle cell lymphomas.                    Clin Cancer Res. 2015; 21: 1835-1842.","DOI":"10.1158\/1078-0432.CCR-14-2221"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20045\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T04:33:38Z","timestamp":1616214818000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/61\/1\/61_20045\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20045","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021]]}}}